Duchenne muscular dystrophy (DMD) therapeutics helps treat genetic disorder caused due to absence of dystrophin, a protein in the body. The symptoms of the disease include weakness in the muscles of the hips, pelvic area, thighs, and shoulders, and later in the muscles of arms, legs, and trunk.
Report Code : A03755 | Category : Life Sciences
The global spinal muscular atrophy treatment market was valued at $4.3 billion in 2022, and is projected to reach $8.4 billion by 2032, growing at a CAGR of 6.8% from 2023 to 2032.
Report Code : A107144 | Pages : 239 | Category : Life Sciences
Bulbospinal muscular atrophy, also referred as Kennedy disease, is a disorder that affects the specific nerve cells in the brain that controls muscle movement. These nerve cells originate ...
Report Code : A11915 | Category : Life Sciences
Vascular dressings are also known as intravenous site dressings are used for protection of the vascular site having an injury. These are used to prevent infections that can ...
Report Code : A12685 | Category : Life Sciences
The global Duchenne muscular dystrophy market size was valued at $1,301.44 Million in 2021, and is estimated to reach $2,073.91 Million by 2031, growing at a CAGR of 4.7% from 2022 to 2031.
Report Code : A15646 | Pages : 143 | Category : Life Sciences
